ICPTUSD

Intercept Pharmaceuticals In

+$373.8M

Net Activity

Institutions Holding

157

Popularity Rank

#2813

Avg Weight

0.19%

Total Value

$781.9M

Ownership Trend

157 institutions currently hold ICPTUSD, with 26 net buyers and 16 net sellers this quarter.

Institutional Moves

Institutional Moves (Q3 2023)

Majority Increased

Based on recent trading activity

Net Selling Institutions

16

Net Buying Institutions

26

Key Holders

View all 157 holding institutions

Quarterly Activity

Recent Activity

+$125.6M

Total Buy Value

$119.1M

Total Sell Value

New buy10
Trim13
Add16
Sold out3

26

Net Buyers

16

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding INTERCEPT PHARMACEUTICALS IN (ICPTUSD)?
Major stakeholders currently include BlackRock Inc. ($78.1M), State Street CORP ($59.3M), UBS Group AG ($55.8M). Based on the latest 13F filings, there are a total of 157 tracked investment funds and institutions maintaining positions in ICPTUSD.
What is the overall institutional sentiment toward ICPTUSD recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $373.8M, driven by 26 managers accumulating shares while 16 reduced their exposure.
Which institutions have been selling or reducing their ICPTUSD positions?
In the latest period, 13 funds trimmed their holdings, and 3 managers completely exited their positions. The aggregate reported sell value was $119.1M.
Are there any notable investors adding ICPTUSD to their portfolios?
Yes, buying activity remains notable. 10 institutions opened new positions in {ticker}, and 16 existing holders added to their shares. The total reported buy value for the quarter amounted to $125.6M.

Related Stocks